about
The implication and potential applications of high-mobility group box 1 protein in breast cancerPotential prognostic, diagnostic and therapeutic markers for human gastric cancerCanine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistryTumour biomarkers: homeostasis as a novel prognostic indicatorMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerEmbryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.Where now for anti-EGF receptor therapies in colorectal cancer?Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancerGlycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study.Triple negative invasive lobular carcinoma of the breast presents as small bowel obstructionLapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsMelatonin Attenuates Her-2, p38 MAPK, p-AKT, and mTOR Levels in Ovarian Carcinoma of Ethanol-Preferring RatsThe advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Optimization of personalized therapies for anticancer treatmentActivation of integrin-ERBB2 signaling in undifferentiated thyroid cancer.Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.Transducin (β)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.Novel points of attack for targeted cancer therapy.High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumorsDocumentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal DoxorubicinBreast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 statusFully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer.Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancerA systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis.TREATMENT OF BREAST CANCER: IMO STATE NIGERIA VERSUS INDIANA, USA WOMEN - COMPARATIVE ANALYTIC STUDY.Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancerCombination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.Advanced breast cancer: aetiology, treatment and psychosocial features.Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro?EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
P2860
Q26744069-9BF22EF7-453D-4218-A05A-317E38275C86Q26866200-DC22EDC0-4844-46D6-8283-E8E28F9CC5ABQ27026594-E2C57C23-0264-43BC-A845-6F8E91E26A4FQ28069898-79725BCB-912F-476B-8C7F-ED2EFEFAAEE2Q28072513-E2AB84AC-73FE-4BAD-87E5-6E257B3242F1Q30403182-EA1F1BF3-ED41-4FEC-9BA2-9447354F6F38Q30437453-DB02E5CB-F4F1-4FE9-95CC-563CC5747024Q31038305-A4640287-2E82-4A6A-B75C-05F2E59839A2Q33533628-5595F457-7EC3-45F3-ACF7-05475DB13FDBQ33551688-0380181F-5C9E-4564-B69F-51AB0A2C2127Q33565890-62159E6E-B3A2-41EF-BDAD-C8A68FCA14A0Q33825133-83A8DA73-D267-4AA6-973E-F549C3A48A3AQ33861915-19F1DDAD-DE7B-47E9-8476-40A001BB4815Q33957896-08896EEE-2210-4980-8DA4-2B5BC4E91542Q34128501-115A7190-E9B8-4894-A5BE-08654446D2D3Q34223494-A91BFB35-344D-4038-8B9D-A6793FBE2304Q34438693-C33C3CFE-E9FE-440F-9BBB-2B7574C57468Q34648886-168BAB76-8E7B-4C53-AD9D-892E947A7532Q34669425-A98ABAED-D1EE-4C11-A2CE-3D75A35E15BCQ34704914-757EF8C7-2CAD-4FF1-8459-8CC311B5C175Q34756800-ED7C4EE8-4E26-4C81-B50A-354C9A6B438EQ35000357-BB1A8F1F-A4F8-4E7F-82B0-56B0ABA209A6Q35023279-8FB22030-8102-4D90-BF73-A35CE679D678Q35078859-631B48E9-79B5-48AE-876E-B48291A9CE92Q35181016-4736D578-72E3-4382-A3EC-40BE0250017EQ35490056-193B3046-684C-4D19-B09D-7BAD4B6B16CFQ35583711-529530C4-3CCF-42CE-A32F-7B102E10F812Q35628492-971582A1-5C5A-4C4A-9150-AF3945832F89Q35670290-9DA8CDE0-9F99-4E14-ACA5-1F6912800440Q35782291-49C1F6FD-76A8-4ED0-8639-363485DC44FDQ35855667-003CB56A-6013-40E1-8F97-04F4F54751B4Q36018383-63B3A427-1BB3-4A0B-835C-1EF3E1398FA6Q36098713-665F0098-4ABF-40B4-A51D-09B15985F5E8Q36258125-D797E0A3-7136-4EF1-BF2B-822267EA1A4CQ36337372-385B158F-4341-44EB-94E3-B7AD91F6B36BQ36498243-0ACA5066-397D-4DFA-8E51-2F5FB2541672Q36627997-2A7F7AC7-F95B-414E-8D9D-E78038BF203AQ36758254-9CE52EE9-BAB3-44F9-9F07-40F943D30989Q36958226-98A50FA9-D099-4E2D-9525-96A7C797F247Q36962490-974CEDF9-8BAA-4ECC-A90E-62842A4FFC71
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The distinctive nature of HER2-positive breast cancers
@ast
The distinctive nature of HER2-positive breast cancers
@en
The distinctive nature of HER2-positive breast cancers
@nl
type
label
The distinctive nature of HER2-positive breast cancers
@ast
The distinctive nature of HER2-positive breast cancers
@en
The distinctive nature of HER2-positive breast cancers
@nl
prefLabel
The distinctive nature of HER2-positive breast cancers
@ast
The distinctive nature of HER2-positive breast cancers
@en
The distinctive nature of HER2-positive breast cancers
@nl
P3181
P356
P1476
The distinctive nature of HER2-positive breast cancers
@en
P2093
Harold J Burstein
P304
P3181
P356
10.1056/NEJMP058197
P407
P577
2005-10-20T00:00:00Z